

Water

Only a negligible part of Lundbeck's global operations, including suppliers, occurs in classified high-risk areas in relation to the water resource. Additionally, Lundbeck maintains limited water withdrawal for production and research activities within our operations. We do not operate in areas of high-water risk, and only 5% of our total water withdrawal occurs in regions classified by the World Wildlife Foundation (WWF) as high-water stress.

Our commitment

Lundbeck recognises the challenges posed by the scarcity of clean water as a significant threat to public health and the environment, and we take these pressures seriously. Although water withdrawal is not currently classified as one of the company's material sustainability topics, we address related risks primarily through our commitment to responsible water usage and wastewater management.

We are dedicated to reducing our environmental impact by quantifying water withdrawal, minimising water consumption, and proactively managing wastewater emissions across all research and production facilities. This commitment includes setting reduction targets at local sites, supported by dedicated optimisation initiatives aimed at lowering our overall impact.

Furthermore, we acknowledge the potential risks that API and chemical residues may pose to aquatic ecosystems, particularly from medicinal residues in our manufacturing processes and patients. To address this, we actively monitor the environmental effects of active pharmaceutical ingredients in our new medicinal products. Through necessary biological and physical/chemical studies, we assess the impact on various aquatic organisms as part of our Environmental Risk Assessment process. The knowledge gained from these assessments drives our manufacturing processes to ensure the least possible environmental impact.

In addition, we are committed to enhancing our understanding of how to measure the risks and impacts related to water sustainability. This ongoing effort enables us to monitor changes in the relevance of these issues within our environmental and business management practices each year.

Lundbeck also supports the Eco-Pharmaco-Stewardship initiative through our membership in European Federation of Pharmaceutical Industries and Associations (EFPIA), which considers the entire lifecycle of pharmaceuticals, further reinforcing our commitment to protecting ecosystems and promoting sustainable practices.

Our future challenges and opportunities:

- Improving our mapping and analysing the differences in water withdrawal at our sites for production, research, and development to identify possibilities for reducing water withdrawal.

- Obtain eco-toxicological knowledge about active pharmaceutical ingredients in our wastewater when introducing new pharmaceuticals into the market.
- Support initiatives to improve data quality and minimise the presence and effects of pharmaceuticals in the environment. E.g., by participating in European and national industry networks to share experience and supporting the Urban Wastewater Treatment Directive (UWWTD).
- Assessing and understanding water-related risks and opportunities in our operations.
- Work proactively with reduction initiatives and take best practice actions in recycling, reuse, or storage of water.
- Reducing our water intensity score (12.9 m³/million DKK revenue in 2024).
- Maintaining our environmental focus concerning water use and wastewater in supplier audits.
- Keeping an open and honest dialogue by disclosing our performance on our homepage and in [Carbon Disclosure Project](#) (CDP).